Preferred Label : Faricimab;

NCIt synonyms : Faricimab-svoa;

NCIt definition : A humanized bispecific antibody targeting both vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2; Ang2; ANGPT2), that is used for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular edema. Upon intravitreal administration, faricimab targets and binds to both VEGF-A and Ang-2, and prevents VEGF-A- and Ang-2-mediated signaling. The inhibition of VEGF-A-mediated signaling decreases endothelial cell proliferation, neovascularization and vascular permeability. The inhibition of Ang-2-mediated signaling improves vascular stability and desensitizes blood vessels to the effects of VEGF-A. VEGF and Ang-2, upregulated in some eye diseases, play important roles in pathological neovascularization and increased vascular permeability and inflammation, which may lead to vision loss.;

UNII : QC4F7FKK7I;

CAS number : 1607793-29-2;

Drug name : Vabysmo;

Molecule name : RO 6867461; RO-6867461; RG 7716; RG-7716;

NCI Metathesaurus CUI : CL1412159;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://www.cadth.ca/fr/faricimab
2022
false
false
false
Canada
French
drug evaluation
Faricimab
faricimab

---
https://www.ema.europa.eu/en/medicines/human/EPAR/vabysmo
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Faricimab
Faricimab
faricimab
antibodies, monoclonal
antibodies, monoclonal
wet macular degeneration
intravitreal injections
vascular endothelial growth factor a
Angiopoietin-2
product surveillance, postmarketing
pregnancy
breast feeding
drug evaluation, preclinical
macular edema
diabetes complications

---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/default-d6182e9e12-38.html
2022
false
false
false
Canada
French
Faricimab
canada
insurance, health, reimbursement
drug evaluation
macular degeneration
faricimab

---
Nous contacter.
31/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.